Primary neuroendocrine tumors of the thymus.
Primary neuroendocrine tumors of the thymus are highly aggressive tumors that rarely occur. A little more than 200 cases have been reported, many of which were single case reports. Only a few articles contained modest series from single centers for analysis. A review of 157 cases collected from the major series reported to-date show a clinical pattern with male preponderance (male:female ratio, 3:1) and a mean age of 54 years. Most patients presented with symptoms and signs of local compression. Almost 50% of these tumors were functionally active and were associated with endocrinopathies. Several histologic variants have been described, all with similar ultrastructural features. The biologic behavior of these tumors shows a direct relation to the degree of differentiation. Whenever possible, surgical resection is the treatment of choice as adjuvant therapy is controversial and has been used with variable success. Potential therapies exploit the presence of somatostatin receptors on a variety of these tumors. Use of radiolabeled Octreotide for radionuclide therapy has yielded tumor inhibition in animal models and may have clinical application. Fifty-one percent of the patients survived 3 years, 27% survived 5 years, and less than 10% survived beyond 10 years. Histologic grade, tumor extension, and early detection are the most important factors affecting survival. Other prognostic factors that impact outcome include presence of endocrinopathy, incomplete resectability, nodal status, and presence of distant metastasis.
Chaer
Rabih
R
Department of Surgery, The University of Illinois at Chicago, 60612, USA.
Massad
Malek G
MG
Evans
Alexander
A
Snow
Norman J
NJ
Geha
Alexander S
AS
D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D009384:Paraneoplastic Endocrine Syndromes / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate; D013934:Thymectomy; D013950:Thymus Gland / Q000473:pathology; D013953:Thymus Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*